Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report
Primary colon squamous cell carcinoma (SCC) is extremely rare and associated with a poor prognosis. Moreover, there is no treatment guideline for this disease. Proficient mismatch repair/microsatellite-stable (pMMR/MSS) colorectal adenocarcinoma is refractory to immune monotherapy. Although the comb...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1051786/full |
| _version_ | 1811157798169346048 |
|---|---|
| author | Yan Liu Junliang Du Pan Zhang Wenjuan Meng Haifeng Xiao |
| author_facet | Yan Liu Junliang Du Pan Zhang Wenjuan Meng Haifeng Xiao |
| author_sort | Yan Liu |
| collection | DOAJ |
| description | Primary colon squamous cell carcinoma (SCC) is extremely rare and associated with a poor prognosis. Moreover, there is no treatment guideline for this disease. Proficient mismatch repair/microsatellite-stable (pMMR/MSS) colorectal adenocarcinoma is refractory to immune monotherapy. Although the combination of immunotherapy with chemotherapy in pMMR/MSS colorectal cancer (CRC) is currently under investigation, the clinical activity of this approach in colorectal SCC remains unknown. In this article, we report the case of a pMMR/MSS CRC patient with ascending colon SCC who had high programmed cell death–ligand 1 (PD-L1) expression and the a missense mutation in codon 600 of the B-Raf proto-oncogene (BRAF V600E) mutation. The patient exhibited a significant response to the combination of immunotherapy and chemotherapy. After eight cycles of treatment with the combination of sintilimab and mFOLFOX6 (oxaliplatin, fluorouracil, and leucovorin), computed tomography–guided microwave ablation of the liver metastasis was performed. The patient achieved excellent durable response and continues to experience a good quality of life. The present case indicates that programmed cell death 1 blockade combined with chemotherapy may be an effective therapy for patients with pMMR/MSS colon SCC and high PD-L1 expression. Furthermore, PD-L1 expression may be a biomarker for immunotherapy in patients with colorectal SCC. |
| first_indexed | 2024-04-10T05:13:29Z |
| format | Article |
| id | doaj.art-2412defdaafa4b62b0a29723f937e7b9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T05:13:29Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2412defdaafa4b62b0a29723f937e7b92023-03-09T05:45:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.10517861051786Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case reportYan LiuJunliang DuPan ZhangWenjuan MengHaifeng XiaoPrimary colon squamous cell carcinoma (SCC) is extremely rare and associated with a poor prognosis. Moreover, there is no treatment guideline for this disease. Proficient mismatch repair/microsatellite-stable (pMMR/MSS) colorectal adenocarcinoma is refractory to immune monotherapy. Although the combination of immunotherapy with chemotherapy in pMMR/MSS colorectal cancer (CRC) is currently under investigation, the clinical activity of this approach in colorectal SCC remains unknown. In this article, we report the case of a pMMR/MSS CRC patient with ascending colon SCC who had high programmed cell death–ligand 1 (PD-L1) expression and the a missense mutation in codon 600 of the B-Raf proto-oncogene (BRAF V600E) mutation. The patient exhibited a significant response to the combination of immunotherapy and chemotherapy. After eight cycles of treatment with the combination of sintilimab and mFOLFOX6 (oxaliplatin, fluorouracil, and leucovorin), computed tomography–guided microwave ablation of the liver metastasis was performed. The patient achieved excellent durable response and continues to experience a good quality of life. The present case indicates that programmed cell death 1 blockade combined with chemotherapy may be an effective therapy for patients with pMMR/MSS colon SCC and high PD-L1 expression. Furthermore, PD-L1 expression may be a biomarker for immunotherapy in patients with colorectal SCC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1051786/fullascending colonsquamous cell carcinomaimmunotherapychemotherapypMMR/MSSBRAF V600E |
| spellingShingle | Yan Liu Junliang Du Pan Zhang Wenjuan Meng Haifeng Xiao Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report Frontiers in Oncology ascending colon squamous cell carcinoma immunotherapy chemotherapy pMMR/MSS BRAF V600E |
| title | Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report |
| title_full | Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report |
| title_fullStr | Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report |
| title_full_unstemmed | Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report |
| title_short | Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report |
| title_sort | squamous cell carcinoma of ascending colon with pmmr mss showed a partial response to pd 1 blockade combined with chemotherapy a case report |
| topic | ascending colon squamous cell carcinoma immunotherapy chemotherapy pMMR/MSS BRAF V600E |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1051786/full |
| work_keys_str_mv | AT yanliu squamouscellcarcinomaofascendingcolonwithpmmrmssshowedapartialresponsetopd1blockadecombinedwithchemotherapyacasereport AT junliangdu squamouscellcarcinomaofascendingcolonwithpmmrmssshowedapartialresponsetopd1blockadecombinedwithchemotherapyacasereport AT panzhang squamouscellcarcinomaofascendingcolonwithpmmrmssshowedapartialresponsetopd1blockadecombinedwithchemotherapyacasereport AT wenjuanmeng squamouscellcarcinomaofascendingcolonwithpmmrmssshowedapartialresponsetopd1blockadecombinedwithchemotherapyacasereport AT haifengxiao squamouscellcarcinomaofascendingcolonwithpmmrmssshowedapartialresponsetopd1blockadecombinedwithchemotherapyacasereport |